Teacher Retirement System of Texas Boosts Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Teacher Retirement System of Texas raised its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 18.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,969 shares of the company’s stock after purchasing an additional 3,736 shares during the period. Teacher Retirement System of Texas’ holdings in CRISPR Therapeutics were worth $943,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CRSP. Wilmington Savings Fund Society FSB purchased a new position in shares of CRISPR Therapeutics in the 3rd quarter valued at $40,000. Highline Wealth Partners LLC purchased a new position in shares of CRISPR Therapeutics during the fourth quarter worth about $39,000. Western Pacific Wealth Management LP increased its position in shares of CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares in the last quarter. Spire Wealth Management lifted its holdings in shares of CRISPR Therapeutics by 303.7% in the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after purchasing an additional 1,482 shares during the last quarter. Finally, MCF Advisors LLC acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at about $80,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on CRSP shares. Chardan Capital cut their price target on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Truist Financial upped their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, February 12th. Morgan Stanley raised their price objective on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research report on Friday, February 14th. Evercore ISI raised shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and upped their target price for the company from $60.00 to $99.00 in a report on Friday, February 14th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus target price of $73.11.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock opened at $36.99 on Friday. The company has a market cap of $3.17 billion, a P/E ratio of -8.46 and a beta of 1.77. CRISPR Therapeutics AG has a one year low of $36.52 and a one year high of $68.39. The business has a fifty day moving average of $43.10 and a two-hundred day moving average of $45.17.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Sell-side analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the transaction, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel James R. Kasinger sold 2,850 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the sale, the general counsel now owns 77,530 shares in the company, valued at $3,288,822.60. This represents a 3.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,381 shares of company stock valued at $1,608,243 in the last quarter. 4.10% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.